Wang et al. conducted a pooled analysis of 196 patients with uncommon EGFR mutations in a NSCLC population treated with either afatinib (N = 125) or osimertinib (N = 71) [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.